GlassScriptPhysician profile
Laura A Lindauer
NPI 1043365109
$1,268.85
in general payments reported to CMS, 2019-2025
25 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $43.63 · 2023: $264 · 2024: $230 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $172.53 | 2023 | Trelegy Ellipta |
| Lilly USA, LLC | $133.57 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $132.59 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $120.91 | 2021-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.91 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $96.56 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $76.31 | 2021-2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $56.36 | 2021 | |
| Abbvie INC. | $49.14 | 2021 | |
| Astellas Pharma US INC | $37.12 | 2023-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $29.96 | 2021 | |
| Pfizer INC. | $28.64 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $28.57 | 2021 | |
| Abbott Laboratories | $20.12 | 2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $17.84 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $17.44 | 2024 | |
| Merck Sharp & Dohme LLC | $17.20 | 2021 | |
| Amarin Pharma, INC. | $16.95 | 2021 | |
| Genentech USA, INC. | $16.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.67 | 2023 | |
| Xeris Pharmaceuticals, INC. | $14.36 | 2025 | Gvoke Hypopen |
| Jazz Pharmaceuticals INC. | $13.96 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.54 | 2024 | Voquezna |
| Medtronic, INC. | $12.54 | 2021 | |
| Esperion Therapeutics, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Lindauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.